CN107074773A - 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途 - Google Patents

取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途 Download PDF

Info

Publication number
CN107074773A
CN107074773A CN201580060830.6A CN201580060830A CN107074773A CN 107074773 A CN107074773 A CN 107074773A CN 201580060830 A CN201580060830 A CN 201580060830A CN 107074773 A CN107074773 A CN 107074773A
Authority
CN
China
Prior art keywords
mmol
methyl
mixture
compound
fluorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580060830.6A
Other languages
English (en)
Chinese (zh)
Inventor
H.贝克
T.塔勒
R.卡斯特
D.梅博姆
M.梅宁格豪斯
C.特荣格
M.德贝克
K.鲁斯蒂格
U.穆恩斯特
B.奥勒尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN107074773A publication Critical patent/CN107074773A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580060830.6A 2014-09-09 2015-09-07 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途 Pending CN107074773A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14184040.5 2014-09-09
EP14184040 2014-09-09
PCT/EP2015/070318 WO2016037954A1 (de) 2014-09-09 2015-09-07 Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung

Publications (1)

Publication Number Publication Date
CN107074773A true CN107074773A (zh) 2017-08-18

Family

ID=51492240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580060830.6A Pending CN107074773A (zh) 2014-09-09 2015-09-07 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途

Country Status (6)

Country Link
US (2) US10189788B2 (enExample)
EP (1) EP3191452A1 (enExample)
JP (1) JP6618530B2 (enExample)
CN (1) CN107074773A (enExample)
CA (1) CA2960324A1 (enExample)
WO (1) WO2016037954A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189788B2 (en) * 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
EP3271334A1 (de) * 2015-03-18 2018-01-24 Bayer Pharma Aktiengesellschaft Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung
PE20191616A1 (es) 2017-04-10 2019-11-05 Bayer Ag N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
KR20260041890A (ko) 2023-07-26 2026-03-27 훼링 비.브이. 소분자 프로스타글란딘 f 수용체 길항제
WO2025189066A1 (en) * 2024-03-08 2025-09-12 Athira Pharma, Inc. Modulators of g protein-coupled receptor 55 (gpr55)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002509A1 (en) * 1994-07-14 1996-02-01 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives as nk3 antagonists
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531458T2 (de) 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CN1660811A (zh) * 2004-02-27 2005-08-31 中国科学院上海药物研究所 1，4－二取代苯类化合物及其制备方法和用途
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
BRPI1013392A2 (pt) 2009-03-31 2016-03-29 Renascience Co Ltd inibidor do inibidor-1 do ativador do plasminogênio
JP2011042643A (ja) 2009-07-24 2011-03-03 Bayer Cropscience Ag 殺虫性カルボキサミド類
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2013074059A2 (en) 2010-11-05 2013-05-23 Regents Of The University Of Minnesota Cytosine deaminase modulators for enhancement of dna transfection
WO2013164326A1 (en) 2012-05-03 2013-11-07 Takeda Gmbh Novel ep2 receptor agonists
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
AU2014209107B2 (en) 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
JP6200596B2 (ja) * 2013-12-17 2017-09-20 イーライ リリー アンド カンパニー ジメチル安息香酸化合物
US10189788B2 (en) * 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002509A1 (en) * 1994-07-14 1996-02-01 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives as nk3 antagonists
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators

Also Published As

Publication number Publication date
EP3191452A1 (de) 2017-07-19
US10189788B2 (en) 2019-01-29
US20190002409A1 (en) 2019-01-03
JP2017526701A (ja) 2017-09-14
JP6618530B2 (ja) 2019-12-11
US20170260140A1 (en) 2017-09-14
WO2016037954A1 (de) 2016-03-17
US10479765B2 (en) 2019-11-19
CA2960324A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
US10479765B2 (en) Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
US10117864B2 (en) Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
JP6367421B2 (ja) 二環で置換されたウラシル類およびそれの使用
US9695131B2 (en) Substituted uracils as chymase inhibitors
AU2016365676A1 (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of TASK-1 and TASK-2 channels, for the treatment of sleep-related breathing disorders
CN110719911A (zh) 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途
CN104822661A (zh) 新的5-氨基四氢喹啉-2-羧酸及其用途
CA3031136A1 (en) Substituted imidazo[1,2-a]pyridin-3-yl compounds and their use for the treatment and/or prevention of respiratory disorders
CN105793267B (zh) 环状噻吩并尿嘧啶甲酰胺类及其用途
JP2013523846A (ja) タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用
JP2013177318A (ja) ジヒドロピリミジノン誘導体およびその医薬用途
KR20230019880A (ko) Lpa 수용체 길항제 및 이의 용도
CN110709384A (zh) 取代的n-芳基乙基-2-氨基喹啉-4-甲酰胺及其用途
WO2017153234A1 (de) Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
JP7107963B2 (ja) 置換されたｎ－アリールエチル－２－アリールキノリン－４－カルボキサミド類及びそれの使用
HK40015123A (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
EA040284B1 (ru) Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды, способ их получения и лекарственное средство, содержащее указанное соединение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818